PDS Biotechnology Corporation (NASDAQ: PDSB) on Monday, soared 9.24% from the previous trading day, before settling in for the closing price of $1.19. Within the past 52 weeks, PDSB’s price has moved between $0.85 and $4.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.42%. The company achieved an average annual earnings per share of 20.71%. With a float of $44.87 million, this company’s outstanding shares have now reached $46.63 million.
Let’s determine the extent of company efficiency that accounts for 24 employees.
PDS Biotechnology Corporation (PDSB) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of PDS Biotechnology Corporation is 3.78%, while institutional ownership is 15.88%. The most recent insider transaction that took place on Feb 28 ’25, was worth 25,000. In this transaction Director of this company bought 15,060 shares at a rate of $1.66, taking the stock ownership to the 61,213 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director bought 15,061 for $1.66, making the entire transaction worth $25,001. This insider now owns 78,851 shares in total.
PDS Biotechnology Corporation (PDSB) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.29 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.28) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.84% during the next five years compared to 6.42% growth over the previous five years of trading.
PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators
PDS Biotechnology Corporation (PDSB) is currently performing well based on its current performance indicators. A quick ratio of 2.92 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.92, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of PDS Biotechnology Corporation (PDSB)
Looking closely at PDS Biotechnology Corporation (NASDAQ: PDSB), its last 5-days average volume was 0.94 million, which is a jump from its year-to-date volume of 0.55 million. As of the previous 9 days, the stock’s Stochastic %D was 43.55%.
During the past 100 days, PDS Biotechnology Corporation’s (PDSB) raw stochastic average was set at 42.25%, which indicates a significant decrease from 58.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0895 in the past 14 days, which was lower than the 0.1052 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2708, while its 200-day Moving Average is $1.5060. However, in the short run, PDS Biotechnology Corporation’s stock first resistance to watch stands at $1.4335. Second resistance stands at $1.5671. The third major resistance level sits at $1.6641. If the price goes on to break the first support level at $1.2029, it is likely to go to the next support level at $1.1059. Now, if the price goes above the second support level, the third support stands at $0.9723.
PDS Biotechnology Corporation (NASDAQ: PDSB) Key Stats
Market capitalization of the company is 60.62 million based on 46,633K outstanding shares. Right now, sales total 0 K and income totals -37,610 K. The company made 0 K in profit during its latest quarter, and -9,430 K in sales during its previous quarter.
